SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+16.81%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$268M
AUM Growth
+$268M
(-9.4%)
Cap. Flow
+$4.07M
Cap. Flow
% of AUM
1.52%
Top 10 Holdings %
Top 10 Hldgs %
40.75%
Holding
95
New
14
Increased
33
Reduced
15
Closed
23
Top Buys
| 1 |
Soleno Therapeutics
SLNO
|
$10.9M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$7.76M |
| 3 |
UroGen Pharma
URGN
|
$7.13M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
$6.54M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
$6.41M |
Top Sells
| 1 |
Akero Therapeutics
AKRO
|
$10.6M |
| 2 |
MoonLake Immunotherapeutics
MLTX
|
$10.2M |
| 3 |
Schrodinger
SDGR
|
$7.23M |
| 4 |
Krystal Biotech
KRYS
|
$5.5M |
| 5 |
89bio
ETNB
|
$5.19M |
Sector Composition
| 1 | Healthcare | 99.9% |
| 2 | Consumer Staples | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Vertex Pharmaceuticals
VRTX
$100B
| $4.79M | 1.45% |
13,765
+590
| +4% | +$205K |
|
27
Gilead Sciences
GILD
$140B
| $4.71M | 1.43% |
62,789
+2,341
| +4% | +$175K |
|
28
Pliant Therapeutics
PLRX
$101M
| $4.34M | 1.32% |
250,409
+143,142
| +133% | +$2.48M |
|
29
Caribou Biosciences
CRBU
$174M
| $4.27M | 1.29% |
+892,786
| New | +$4.27M |
|
30
TELA Bio
TELA
$70.5M
| $3.92M | 1.19% |
490,471
+74,031
| +18% | +$592K |
|
31
Insmed
INSM
$28.8B
| $3.8M | 1.15% |
150,387
+5,923
| +4% | +$150K |
|
32
Mirum Pharmaceuticals
MIRM
$3.71B
| $3.48M | 1.06% |
110,114
+3,739
| +4% | +$118K |
|
33
Zura Bio
ZURA
$133M
| $2.67M | 0.81% |
404,040
+244,040
| +153% | +$1.61M |
|
34
Terns Pharmaceuticals
TERN
$609M
| $2.52M | 0.76% |
500,000
-99,668
| -17% | -$501K |
|
|
MTEM
35
DELISTED
Molecular Templates, Inc.
MTEM
| $2.24M | 0.68% |
+354,608
| New | +$2.24M |
|
36
KalVista Pharmaceuticals
KALV
$678M
| $2.2M | 0.67% |
228,934
-491,574
| -68% | -$4.73M |
|
37
Trevi Therapeutics
TRVI
$883M
| $2.02M | 0.61% |
927,415
+41,491
| +5% | +$90.5K |
|
38
Kodiak Sciences
KOD
$478M
| $2.01M | 0.61% |
+1,114,461
| New | +$2.01M |
|
39
Cerus
CERS
$251M
| $1.95M | 0.59% |
1,203,890
+45,625
| +4% | +$73.9K |
|
40
Xenon Pharmaceuticals
XENE
$2.98B
| $1.84M | 0.56% |
53,996
-45,760
| -46% | -$1.56M |
|
41
Evogene
EVGN
$10.9M
| $1.82M | 0.55% |
3,100,000
+3,000,000
| +3,000% | +$1.76M |
|
42
Intellia Therapeutics
NTLA
$1.22B
| $1.68M | 0.51% |
53,018
+2,160
| +4% | +$68.3K |
|
|
43
Akero Therapeutics
AKRO
$3.74B
| $1.58M | 0.48% |
31,336
-210,021
| -87% | -$10.6M |
|
|
JBIO
44
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $1.36M | 0.41% |
+100,000
| New | +$1.36M |
|
45
Prothena Corp
PRTA
$441M
| $1.28M | 0.39% |
26,629
-23,092
| -46% | -$1.11M |
|
46
Roivant Sciences
ROIV
$8.15B
| $1.17M | 0.35% |
+100,000
| New | +$1.17M |
|
47
Alkermes
ALKS
$4.78B
| $1.16M | 0.35% |
41,455
+1,455
| +4% | +$40.8K |
|
48
Sarepta Therapeutics
SRPT
$1.78B
| $1.11M | 0.34% |
9,197
-20,663
| -69% | -$2.5M |
|
49
Annexon
ANNX
$226M
| $943K | 0.29% |
399,716
+9,805
| +3% | +$23.1K |
|
|
50
89bio
ETNB
$1.34B
| $930K | 0.28% |
60,247
-336,250
| -85% | -$5.19M |
|